drugset / Trial / NCT03959176

The Effect of Brimonidine

NCT03959176

Phase 4 Completed 13 enrolled Wake Forest University Health Sciences
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will evaluate whether pre-treating patients with Brimonidine 0.2% before and/or after dilating the pupils will help to control the changes in intraocular pressure often seen when using dilating drops. The study will also evaluate the effects of different sequences of administering dilating drops along with Brimonidine on pupil size and reactivity.

Timeline

Start
2019-07-20
Primary completion
2019-07-20
Completion
2019-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Topical
Background Phenylephrine Small molecule 2.5 % Topical
Background tropicamide Small molecule 1 % Topical

Indications